These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. Sacks CA; Avorn J; Kesselheim AS N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878 [No Abstract] [Full Text] [Related]
3. Controversial Approval of New Drug to Treat Alzheimer's Disease. Aschenbrenner DS Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. Alexander GC; Emerson S; Kesselheim AS JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469 [No Abstract] [Full Text] [Related]
5. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point. Eiser AR Am J Med; 2021 Dec; 134(12):1442-1443. PubMed ID: 34256026 [No Abstract] [Full Text] [Related]
6. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? Schulman KA; Greicius MD; Richman B JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572 [No Abstract] [Full Text] [Related]
7. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. Dunn B; Stein P; Cavazzoni P JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984 [No Abstract] [Full Text] [Related]
8. What the Aducanumab Approval Reveals About Alzheimer Disease Research. Manly JJ; Glymour MM JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885 [No Abstract] [Full Text] [Related]
9. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? Planche V; Villain N JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750 [No Abstract] [Full Text] [Related]
10. FDA Drug Approval and the Ethics of Desperation. Largent EA; Peterson A; Lynch HF JAMA Intern Med; 2021 Dec; 181(12):1555-1556. PubMed ID: 34694325 [No Abstract] [Full Text] [Related]
11. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity? Crosson FJ; Covinsky K; Redberg RF JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992 [No Abstract] [Full Text] [Related]
12. The Problem of Aducanumab for the Treatment of Alzheimer Disease. Alexander GC; Karlawish J Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642 [No Abstract] [Full Text] [Related]
13. A carte blanche approval in Alzheimer's. Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862 [No Abstract] [Full Text] [Related]
14. Aducanumab and the Business of Alzheimer Disease-Some Choice. Karlawish J JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302 [No Abstract] [Full Text] [Related]
15. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Karlawish J; Grill JD Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383 [No Abstract] [Full Text] [Related]
16. US FDA defends approval of Alzheimer's disease drug. Jaffe S Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382 [No Abstract] [Full Text] [Related]
17. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. Robinson JC N Engl J Med; 2021 Nov; 385(22):2017-2019. PubMed ID: 34797614 [No Abstract] [Full Text] [Related]
18. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab. Emanuel EJ JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184 [No Abstract] [Full Text] [Related]
19. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made? Kurkinen M; Tran L J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888 [No Abstract] [Full Text] [Related]
20. A contentious FDA ruling for Alzheimer's disease. The Lancet Neurology Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273 [No Abstract] [Full Text] [Related] [Next] [New Search]